{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-023742","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.222319+00:00","generated_at":"2026-05-26T09:54:39.903554+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Repligen Q4 revenue $168M; FY2024 $634M; guides FY2025 8-12% growth","bullets":["Q4 revenue $168M, flat YoY; FY2024 revenue $634M vs $632M.","GAAP net loss $34M ($0.60 loss per share); adjusted EPS $0.44 vs $0.48.","Orders outpaced sales by 6% in Q4; sequential revenue up 8%.","FY2025 guidance: revenue $685-710M (8-12% reported growth, 10-14% ex-COVID).","Closed acquisition of Tantti Laboratory; launched AVIPure dsRNA resin for mRNA."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-023742","json":"https://secwatch.observer/filing/0000950170-25-023742.json","markdown":"https://secwatch.observer/filing/0000950170-25-023742.md","text":"https://secwatch.observer/filing/0000950170-25-023742.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000095017025023742/0000950170-25-023742-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000095017025023742/rgen-20250220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T09:54:39.903554+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}